Antihypertensive and renal effects of enalapril and slow-release verapamil in essential hypertension. A double-blind, randomized study

The renal, metabolic and antihypertensive effects of enalapril (E) and slow-release verapamil (V) were compared in a 2-month double-blind crossover trial in 22 patients with newly discovered essential hypertension. The glomerular filtration rate and renal vascular resistance were unaltered: renal bl...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of clinical pharmacology Vol. 39 Suppl 1; p. S41
Main Authors Fagher, B, Henningsen, N, Hulthén, L, Katzman, P, Thulin, T
Format Journal Article
LanguageEnglish
Published Germany 01.01.1990
Subjects
Adult
Aldosterone - blood
Angiotensin II - blood
Angiotensin II - drug effects
Blood Pressure - drug effects
Delayed-Action Preparations
Double-Blind Method
Enalapril - adverse effects
Enalapril - therapeutic use
Female
Humans
Hypertension - drug therapy
Kidney - drug effects
Male
Middle Aged
Renin - blood
Renin - drug effects
Verapamil - adverse effects
Verapamil - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:The renal, metabolic and antihypertensive effects of enalapril (E) and slow-release verapamil (V) were compared in a 2-month double-blind crossover trial in 22 patients with newly discovered essential hypertension. The glomerular filtration rate and renal vascular resistance were unaltered: renal blood flow was slightly decreased by V. Serum Ca2+ increased and Na+ excretion declined after V. Serum lipids, glucose, and erythrocyte electrolytes were unchanged. Blood pressure (BP) was lower with E after half the maximum dosage compared with V, but similar BP reductions were obtained after 2 months with the maximum dosage.
ISSN:0031-6970
DOI:10.1007/BF01409207